Long-term impact of congenital toxoplasmosis on phenotypic and functional features of circulating leukocytes from infants one year after treatment onset

Clin Immunol. 2021 Nov:232:108859. doi: 10.1016/j.clim.2021.108859. Epub 2021 Sep 23.

Abstract

Changes in immune response of children with congenital toxoplasmosis (CT) regarding infection evolution and therapeutic intervention was addressed. Infants with CT presented increased counts of monocytes, CD3-CD16-CD56High, CD3+CD56+ and CD4+ T-cells 1-year after treatment onset (TOXO1-yearAT). Smaller numbers of CD3-CD16-CD56+ and TCRγδ+ T-cells were specifically observed in infants with retinochoroidal lesions (L(+)). When infants were classified based on the baseline status, expansion of CD3-CD16-CD56High and CD4+ T-cells were observed in L(+) who had active, active/cicatricial or cicatricial lesions. Infants who had active or active/cicatricial lesions display augmented numbers of monocytes, CD3-CD16+CD56+, CD3+CD56+, CD8+DR+ and TCRγδ+ T-cells and those with active/cicatricial or cicatricial at baseline displayed increase in CD14+CD64+ monocytes. Moreover, all L(+) had increased IFN-γ+ and IL-10+ CD4+ T-cells, while L(-) had increased ratios of TNF+, IFN-γ+ and IL-4+ NK-cells upon antigen-specific stimulation. Persistent alterations in leukocytes in TOXO1-yearAT suggest long-term sequels in the immune system of infants with CT.

Keywords: Congenital; Immune response; Infants; Phenotypic and functional biomarkers; Toxoplasmosis.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiprotozoal Agents / adverse effects*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Lymphocytes / drug effects*
  • Male
  • Monocytes / drug effects*
  • Phenotype
  • Pyrimethamine / adverse effects
  • Sulfadiazine / adverse effects
  • Time
  • Toxoplasmosis, Congenital / drug therapy*
  • Toxoplasmosis, Congenital / immunology*

Substances

  • Antiprotozoal Agents
  • Sulfadiazine
  • Pyrimethamine